Organ transplant company Paragonix Technologies scored $24 million in Series B funding led by Signet Healthcare Partners.
The company developed three FDA-cleared and CE-marked devices – Paragonix SherpaPak, LUNGguard Donor Lung Preservation System and the LIVERguard System – that incorporate digital tracking and communication technologies for organ tracking, reporting and monitoring.
The company...
